CRHR2

Across TCGA pan-cancer cohorts, CRHR2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CRHR2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRHR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CRHR2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CRHR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.628	0.455	.003	48	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.624	.007	20	view →
UCEC	OS	Median	II,III,IV	0.628	1.000	.013	8	view →
GBM	DFS	Quartile	All	0.536	0.270	.012	5	view →
HNSC	OS	Quartile	II,III,IV	0.931	1.000	.042	3	view →
LUAD	DFS	Quartile	III,IV	0.625	1.000	.040	1	view →
CCRCC	OS	Tertile	All	1.000	0.712	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CRHR2–PDAC (OS)

Open the PDAC breakdown →